Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. https://www.who.int/publications/m/item/covid-19-weekly-epidemiological-update---21-december-2022 (cited on 02-Jan-2023)
2. Pelly S, Liotta D. Potent SARS-CoV-2 direct-acting antivirals provide an important complement to COVID-19 vaccines. ACS Cent Sci. 2021;7:396–99.
3. Unoh Y, Uehara S, Nakahara K, Nobori H, Yamatsu Y, Yamamoto S, et al. Discovery of S‑217622, a noncovalent oral SARS-CoV‑2 3CL protease inhibitor clinical candidate for treating COVID-19. J Med Chem. 2022;65:6499–512.
4. Fan H, Lou F, Fan J, Li M, Tong Y. The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era. Lancet. 2022;3:e91.
5. https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html (cited on 02-Jan-2023)